Search Results - "Blanc, J F"

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort by Marthey, L., Sa-Cunha, A., Blanc, J. F., Gauthier, M., Cueff, A., Francois, E., Trouilloud, I., Malka, D., Bachet, J. B., Coriat, R., Terrebonne, E., De La Fouchardière, C., Manfredi, S., Solub, D., Lécaille, C., Thirot Bidault, A., Carbonnel, F., Taieb, J.

“…Background First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA)…”
Get full text

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score by Edeline, J., Blanc, J.-F., Campillo-Gimenez, B., Ma, Y.-T., King, J., Faluyi, O., Mathurin, J., Ghazi, S., Palmer, D.H., Meyer, T.

“…No prognostic classification is currently used for patients treated with systemic therapies for Hepatocellular Carcinoma (HCC). We retrospectively analysed…”
Get full text

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib by Decaens, T., Barone, C., Assenat, E., Wermke, M., Fasolo, A., Merle, P., Blanc, J.-F., Grando, V., Bruns, R., Straub, J., Zhao, C., Faivre, S.

Get full text

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial by BOIGE, V, RAOUL, J.-L, PIGNON, J. P, BOUCHE, O, BLANC, J.-F, DAHAN, L, JOUVE, J.-L, DUPOUY, N, DUCREUX, M

“…Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to…”
Get full text

Hepatic angiosarcoma: A suggestive pattern of enhancement on dynamic MR imaging by Cassinotto, C, Rullier, A, Hocquelet, A, Blanc, J.-F, Trillaud, H

Get full text

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma by Abou-Alfa, Ghassan K, Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B, Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Chen, YenHsun, Park, Joong-Won, Blanc, Jean-Frederic, Bolondi, Luigi, Klümpen, Heinz-Josef, Chan, Stephen L, Zagonel, Vittorina, Pressiani, Tiziana, Ryu, Min-Hee, Venook, Alan P, Hessel, Colin, Borgman-Hagey, Anne E, Schwab, Gisela, Kelley, Robin K

“…Among patients with hepatocellular carcinoma whose disease had progressed during receipt of sorafenib or other systemic therapy, median overall survival was…”
Get full text

Carcinome hépatocellulaire : nouveautés épidémiologiques et démarche diagnostique by Blanc, J. -F.

“…Résumé Le carcinome hépatocellulaire (CHC) se développe essentiellement sur cirrhose. Les infections virales chroniques B et C et la consommation excessive…”
Get full text

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE) by Moehler, M., Heo, J., Lee, H.C., Tak, W.Y., Chao, Y., Paik, S.W., Yim, H.J., Byun, K.S., Baron, A., Ungerechts, G., Jonker, D., Ruo, L., Cho, M., Kaubisch, A., Wege, H., Merle, P., Ebert, O., Habersetzer, F., Blanc, J.F., Rosmorduc, Olivier, Lencioni, R., Patt, R., Leen, A.M., Foerster, F., Homerin, M., Stojkowitz, N., Lusky, M., Limacher, J.M., Hennequi, M., Gaspar, N., McFadden, B., De Silva, N., Shen, D., Pelusio, A., Kirn, D.H., Breitbach, C.J., Burke, J.M.

“…Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while…”
Get full text

Predictive factors of depressive symptoms of elderly patients with cancer receiving first‐line chemotherapy by Duc, S., Rainfray, M., Soubeyran, P., Fonck, M., Blanc, J. F., Ceccaldi, J., Cany, L., Brouste, V., Mathoulin‐Pélissier, S.

“…Background Depression is the most common psychiatric disorder in geriatrics and oncology. For elderly cancer patients, it has a significant impact on quality…”
Get full text

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology by Okusaka, T., Blanc, J.-F., Chau, I., Yang, L., Abada, P., Zhu, A.X.

Get full text

Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC) by Decaens, T., Barone, C., Assenat, E., Wermke, M., Fasolo, A., Merle, P., Blanc, J.F., Grando, V., Bruns, R., Straub, J., Zhao, C., Faivre, S.

Get full text

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH) by Zhu, A.X., Finn, R.S., Galle, P.R., Llovet, J.M., Blanc, J.F., Okusaka, T., Chau, I., Cella, D., Girvan, A., Gable, J., Bowman, L., Hsu, Y., Abada, P.B., Kudo, M.

Get full text

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH) by Zhu, A., Finn, R., Galle, P., Llovet, J., Blanc, J F, Okusaka, T., Chau, I., Abada, P., Hsu, Y., Kudo, M.

Get full text

Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) by Blanc, J.F., Meyer, T., Cheng, A.-L., El-Khoueiry, A.B., Cicin, I., Chen, Y., Bolondi, L., Dadduzio, V., Baron, A., Lin, Z.-Z., Adriani, J., Kelly, R.K., Abou-Alfa, G.K.

Get full text

Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma by Le Bail, Brigitte, Faouzi, Saadia, Boussarie, Liliane, Guirouilh, Josée, Blanc, Jean-Frédéric, Carles, Jacques, Bioulac-Sage, Paulette, Balabaud, Charles, Rosenbaum, Jean

“…Osteonectin (ON)/SPARC is a glycoprotein involved in extracellular matrix remodelling. ON expression by myofibroblasts has been reported in fibrotic human…”
Get full text

Comparison of perfused volume segmentation between cone-beam CT and 99mTc-MAA SPECT/CT for treatment dosimetry before selective internal radiation therapy using 90Y-glass microspheres by Martin, M., Hocquelet, A., Debordeaux, F., Bordenave, L., Blanc, J.-F., Papadopoulos, P., Lapuyade, B., Trillaud, H., Pinaquy, J.-B.

“…•Cone-beam CT may be a reproductible and reliable method for perfused volume segmentation.•Cone-beam CT does not significantly increase accuracy of dose…”
Get full text

Proteomic analysis identifies argininosuccinate synthase 1 as a useful biomarker for hepatocellular adenoma classification and patient management by Abouhammoud, A, Henriet, E, Dupuy, J.-W, Dartigues, B, Ezzoukhry, Z, Senant, N, Blanc, J.-F, Lebail, B, Nikolski, M, Bioulac-Sage, P, Balabaud, C, Raymond, A.-A, Saltel, F

Get full text

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification by Calderaro, J, Couchy, G, Imbeaud, S, Amaddeo, G, Blanc, J.-F, Laurent, C, Hajji, Y, Azoulay, D, Bioulac-Sage, P, Zucman-Rossi, J

Get full text

Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy by Chen, L.-T., Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G.S., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J.-F., Hubner, R., Chiu, C.-F., Schwartsmann, G., Braiteh, F., Belanger, B., Bayever, E., de Jong, F., von Hoff, D.D., Siveke, J.T.

Get full text

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) by Finn, R.S., Kudo, M., Cheng, A-L., Wyrwicz, L., Ngan, R., Blanc, J-F., Baron, A.D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K-H., Qin, S., Minoshima, Y., Funahashi, Y., Ren, M., Dairiki, R., Sachdev, P., Tamai, T., Dutcus, C., Evans, T.R.J.

Get full text